The discussion from “Methodological Issues in Pivotal Trials,” Session 2 of the DIA Workshop “Clinical Trials in Biotechnology: Planning to Prevent the Pitfalls,” is presented. This is an unusual offering for the Drug Information Journal, but the comments are important enough to merit publication.
